The Ink Strikes Back: Tattoo-Associated Uveitis Syndrome. A 5-Case Series

Abstract

Objectives Tattoo-Associated Uveitis Syndrome (TAUS) is a rare immune-mediated condition characterized by synchronous inflammation, including some cases with granulomatous involvement, of tattooed skin and ocular structures, reflecting a hypersensitivity to pigment antigens. This series details the clinical manifestations of 5 patients with TAUS managed at a multidisciplinary tertiary center.[1,2] Methods Five patients were identified through the Uveitis-Rheumatology Collaborative Program (Toronto, Canada) between 2019 and 2025. Demographic, ophthalmologic, dermatologic, and immunologic data were reviewed, including the timing of tattoo reactivation, uveitis phenotype, systemic work-up, treatment, and outcomes. Infectious and systemic autoimmune etiologies were excluded by comprehensive testing such as angiotensine-converting enzyme (ACE), autoantibodies, chest imaging, tuberculosis screening, and biopsy when indicated. Results The cohort comprised 5 adults (3 women, 2 men; mean age 34 years) who all developed ocular inflammation within months of inflammatory changes in long-standing tattoos—manifesting as erythema, induration, or swelling, most often in black or multicolored pigments on the arms, shoulders, or trunk. Latency between tattoo placement and uveitis onset ranged from 6 months to > 5 years (Table 1). Uveitis phenotypes included bilateral anterior (n = 1), anterior-intermediate (n = 1), and panuveitis (n = 3). Two presented with optic-disc edema and 1 with subretinal fluid. Diagnosis was confirmed by biopsy-proven non-caseating granulomas in 2 cases and by elevated ACE with concordant tattoo-ocular activity in 3; none developed systemic sarcoidosis. All received systemic corticosteroids for induction with topical therapy for local control. Methotrexate was first line in 4, with adalimumab escalation in 2 partial responders. One patient required mycophenolate mofetil after steroid-induced hyperglycemia, maintaining remission thereafter. Four achieved ≥12 months of steroid-free quiescence; 1 remains on taper with preserved vision and inactive tattoos. Table 1. Main Clinical Manifestations of Five Patients with Tattoo-Associated Uveitis Syndrome Conclusion TAUS represents a distinctive cutaneous-ocular inflammatory syndrome characterized by concurrent inflammatory activity in tattoos and uveal tissue. Diagnosis relies on the simultaneous inflammation of skin and eye and, although is not always a granulomatous-type inflammation, it is important to rule out this type of involvement with histologic or biochemical evidence due to its particular severity and also to exclude systemic sarcoidosis. Management should combine early systemic corticosteroids with timely transition to steroid-sparing agents—methotrexate or mycophenolate—and escalation to biologics such as adalimumab for refractory or recurrent cases. Continuous communication between ophthalmology, rheumatology, and dermatology is essential. Prompt recognition and multidisciplinary immunosuppression can achieve durable remission, prevent visual loss, and mitigate systemic overtreatment in this pigment-driven disease. References [1.] Kesav NP. J Vitreoretin Dis 2024;8:339-342. [2.] Siebert E. Clin Exp Ophthalmol 2026;54:33-43.